Ciphergen presents advancements in ovarian, breast cancer programs at AACR

By Lisa Kerner

Erie, Pa., April 4 - Ciphergen Biosystems, Inc. highlighted two studies at the American Association of Cancer Research conference in Washington, D.C.

In previous studies, Ciphergen and its collaborators have discovered, identified and validated seven serum/plasma biomarkers for the detection of ovarian cancer, according to a company news release.

An independent validation of the biomarkers by researchers from The Johns Hopkins University School of Medicine, Righospitalet, University of Copenhagen, Denmark, and the Danish Cancer Society, concluded that this seven biomarker panel, in combination with CA-125, improves the discrimination of ovarian cancer from benign pelvic masses, including endometriosis and benign ovarian cysts.

As part of Ciphergen's breast cancer program, researchers reported the latest developments in a paper titled, "Discovery of serum proteomic biomarkers for the early detection of breast cancer- a multi-center study." The company said identification and characterization of these biomarkers are currently underway.

"These studies and others that will be featured at AACR demonstrate the potential for improved patient care as these discoveries are translated into new diagnostic and theranostic tests based on Ciphergen's SELDI ProteinChip Technology," president and chief executive officer Gail S. Page said in the release.

Located in Fremont, Calif., Ciphergen develops, manufactures and markets a family of ProteinChip Systems and services for clinical, research and process proteomics applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.